LivaNova PLC (LIVN) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Devices 산업에서 운영. 본사 소재지는 London, 영국. 현재 CEO는 Vladimir A. Makatsaria.
LIVN 을(를) 보유 IPO 날짜 2015-10-19, 2,900 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $3.55B.
LivaNova PLC is a global medical device company headquartered in London that designs, develops, manufactures, and sells therapeutic solutions across three primary segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment produces heart-lung machines, oxygenators, and perfusion systems for surgical use, while the Neuromodulation segment markets the VNS Therapy System, an implantable device for treating drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea, and is developing the VITARIA System for heart failure treatment. The Advanced Circulatory Support segment provides temporary life support solutions for cardiopulmonary and respiratory support. LivaNova serves hospitals, medical institutions, and healthcare providers worldwide through a network of direct sales representatives and independent distributors, and collaborates with leading organizations such as Verily on clinical research initiatives.
